What's Happening?
Bausch + Lomb has decided to discontinue the development of its glaucoma drug, BL1107, following unsatisfactory results from a phase 2 trial. The drug, an eye drop formulation intended to reduce intraocular pressure and protect vision, failed to demonstrate
significant improvement in visual function over 28 days in patients with primary open-angle glaucoma or ocular hypertension. Despite previous promising results in earlier trials, the drug did not meet secondary objectives, such as improving low-luminance visual acuity. The company will now focus on a sustained-release implant version of BL1107 for treating geographic atrophy (GA), a condition related to age-related macular degeneration (AMD). This new direction is part of Bausch + Lomb's strategy to address a market valued at over $1 billion.
Why It's Important?
The decision to halt the glaucoma drug's development underscores the challenges pharmaceutical companies face in drug development, where not all projects yield successful outcomes. Bausch + Lomb's pivot to focus on geographic atrophy treatments highlights the company's adaptive strategy in leveraging its existing research to target other significant eye conditions. This shift could potentially open new revenue streams, given the substantial market for GA and AMD treatments. The company's collaboration with Ripple Therapeutics on a sustained-release implant could position it as a leader in innovative eye care solutions, potentially benefiting patients with limited treatment options for these conditions.
What's Next?
Bausch + Lomb plans to initiate trials for the sustained-release implant formulation of BL1107 in 2028, with the aim of testing its efficacy in treating geographic atrophy. If successful, this could lead to the first small-molecule sustained-release implant for GA, offering a new treatment modality for patients. The company continues to diversify its pipeline, with ongoing developments in treatments for dry eye disease and ocular surface pain, which could collectively generate over $2 billion in peak sales. This strategic diversification is crucial for maintaining the company's competitive edge in the pharmaceutical industry.
